Natural history of multiple sclerosis symptoms

International Journal of MS Care

Volumn 15, Issue 3, 2013, Pages 146-158

  Kister, Ilya ^a   Bacon, Tamar E ^a   Chamot, Eric ^b   Salter, Amber R ^a   Cutter, Gary R ^c   Kalina, Jennifer T ^a   Herbert, Joseph ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888352123     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2012-053     Document Type: Article

References (28)

1. McDonald I, Compston A. The symptoms and signs of multiple sclerosis. In: Compston A, et al. McAlpine's Multiple Sclerosis. 4th ed. London: Churchill Livingstone; 2006:287-347.
2. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med. 1993;83:325-337.
3. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol. 1987;44:376-378.
4. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology. 1996;46:628-632.
5. Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol. 1999;246:1027-1032.
6. Solaro C, Brichetto G, Amato MP, et al.; PaIMS Study Group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63:919-921
7. Vollmer TL, Ni W, Stanton S, Hadjimichael O. The NARCOMS patient registry: a resource for investigators. Int J MS Care. 1999;1:12-15.
8. NARCOMS-Multiple Sclerosis Patient Registry. http://www.narcoms. org. Accessed November 28, 2012.
9. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler. 2007;13:1176-1182.
10. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler. 2007;13:770-775.
11. Schwartz CE, Vollmer T, Lee H; North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology. 1999;52:63-70.
12. Preiningerova J, Hadjimichael O, Vollmer T, Rizzo M. Validation of patient-reported disease descriptors in the NARCOMS Patient Registry [abstract]. Int J MS Care. 2003;5:126.
13. Mokkink LB, Knol DL, Uitdehaag BMJ. Factor structure of Guy's Neurological Disability Scale in a sample of Dutch patients with multiple sclerosis. Mult Scler. 2011;17:1498-1503.
14. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(pt 7): 1900-1913.
15. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98-108.
16. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology. 2011;76(suppl 1):S14-S25.
17. Tremlett H, YousefiM, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73:1616-1623.
18. Li DK, Held U, Petkau J, et al.; Sylvia Lawry Centre for MS Research. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology. 2006;66:1384-1389.
19. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009;8:280-291.
20. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler. 1999;5:369-376.
21. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74: 2004-2015.
22. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004;56:303-306.
23. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology. 2007;68:496-500.
24. Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain. 2012;135(pt 3):900-911.
25. Leray E, Coustans M, Le Page E, Yaouanq J, Oger J, Edan G. 'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. Mult Scler. 2013;19:458-465.
26. Kister I, Chamot E, Cutter G, et al. Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci. 2012;318:94-99.
27. Kister I, Chamot E, Bacon JH, et al. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Mult Scler. 2011;17:725-733.
28. Kister I, Chamot E, Cutter G, Salter A, Bacon T, Herbert J. Disability in multiple sclerosis: a reference for patients and clinicians. Neurology. 2013;80:1018-1024.